Comprehensive flow cytometry-based diagnosis of XIAP deficiency
- PMID: 40128104
- PMCID: PMC12062573
- DOI: 10.1093/cei/uxaf020
Comprehensive flow cytometry-based diagnosis of XIAP deficiency
Abstract
Deficiency of X-linked inhibitor of apoptosis protein (XIAP) is an X-linked recessive inborn error of immunity characterized by abnormal immune responses leading to inflammatory bowel disease and hemophagocytic lymphohistiocytosis. Although XIAP protein expression analysis by flow cytometry (XIAP flow) is commonly used to diagnose XIAP deficiency, certain variants may not affect the protein expression, thereby complicating the diagnostic process. XIAP is crucial for the nucleotide-binding and oligomerization domain 2 (NOD2) signaling pathway. In this study, we aimed to perform a comprehensive analysis of nine patients diagnosed with XIAP deficiency through genetic testing. In addition to XIAP flow, we employed a previously reported method utilizing muramyl dipeptide (MDP) stimulation, a specific agonist of NOD2, to quantitatively evaluate the downstream tumor necrosis factor-alpha (TNFα) production by flow cytometry in patient monocytes (MDP flow). The median mean fluorescence intensity in healthy controls with XIAP flow was 711 (95% confidence interval [CI], 653-815) compared to 195 (95% CI, 161-386) in patients with XIAP deficiency (P < 0.0001). The median percentage of TNFα-producing monocytes in controls with MDP flow was 29.1% (95% CI, 19.6-53.7), while in patients it was 0.34% (95% CI, 0.18-0.82) (P = 0.0008). The receiver operating characteristic curves demonstrated that both XIAP flow and MDP flow exhibited 100% sensitivity and specificity. Taken together, combining XIAP flow and MDP flow analyses allows for a highly accurate diagnosis.
Keywords: IL-18; NOD2; TNFα; XIAP deficiency; flow cytometry; iNKT cells.
© The Author(s) 2025. Published by Oxford University Press on behalf of the British Society for Immunology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.
Conflict of interest statement
All authors declare that they have no relevant conflict of interest.
References
-
- Mudde ACA, Booth C, Marsh RA.. Evolution of our understanding of XIAP deficiency. Front Pediatr 2021, 9, 660520. doi: https://doi.org/10.3389/fped.2021.660520 - DOI - PMC - PubMed
-
- Aguilar C, Latour S.. X-linked inhibitor of apoptosis protein deficiency: more than an X-linked lymphoproliferative syndrome. J Clin Immunol 2015, 35, 331–8. doi: https://doi.org/10.1007/s10875-015-0141-9 - DOI - PubMed
-
- Bertrand MJ, Doiron K, Labbé K, Korneluk RG, Barker PA, Saleh M.. Cellular inhibitors of apoptosis cIAP1 and cIAP2 are required for innate immunity signaling by the pattern recognition receptors NOD1 and NOD2. Immunity 2009, 30, 789–801. doi: https://doi.org/10.1016/j.immuni.2009.04.011 - DOI - PubMed
-
- Ammann S, Elling R, Gyrd-Hansen M, Dückers G, Bredius R, Burns SO, et al.A new functional assay for the diagnosis of X-linked inhibitor of apoptosis (XIAP) deficiency. Clin Exp Immunol 2014, 176, 394–400. doi: https://doi.org/10.1111/cei.12306 - DOI - PMC - PubMed
-
- Yang X, Kanegane H, Nishida N, Imamura T, Hamamoto K, Miyashita R, et al.Clinical and genetic characteristics of XIAP deficiency in Japan. J Clin Immunol 2012, 32, 411–20. doi: https://doi.org/10.1007/s10875-011-9638-z - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources